Debates between Angela Eagle and Wendy Morton during the 2019-2024 Parliament

Oral Answers to Questions

Debate between Angela Eagle and Wendy Morton
Tuesday 24th November 2020

(4 years, 1 month ago)

Commons Chamber
Read Full debate Read Hansard Text Read Debate Ministerial Extracts
Sara Britcliffe Portrait Sara Britcliffe (Hyndburn) (Con)
- Hansard - - - Excerpts

What diplomatic steps the Government are taking to support the development of a covid-19 vaccine (a) in the UK and (b) throughout the world.

Wendy Morton Portrait The Parliamentary Under-Secretary of State for Foreign, Commonwealth and Development Affairs (Wendy Morton)
- Hansard - - - Excerpts

The UK is committed to rapid, equitable access to safe and effective vaccines through multilateral collaboration. We strongly support the COVAX advance market commitment, which is the international initiative to support global equitable access. The UK is the largest bilateral donor to the AMC, having committed up to £548 million to help provide vaccines for up to 92 developing countries. The UK also committed £71 million in non-official development assistance to participate in the COVAX facility for self-financing countries, in order to secure options to vaccines for UK domestic use.

Angela Eagle Portrait Ms Eagle
- Hansard - -

In a pandemic we are only as strong as our weakest link. Is the Minister convinced that, even though we are one of the largest donors, we are doing enough to ensure that developing nations have the infrastructure they need to organise a mass roll-out of the vaccine?

Wendy Morton Portrait Wendy Morton
- Hansard - - - Excerpts

A pandemic response is absolutely what we need to tackle this virus, and that requires global collaboration. The UK strongly supports multilateral approaches so that we can meet both domestic and global needs, and that work goes alongside UK deals with individual vaccine developers. I am sure that, like me, the hon. Lady will welcome AstraZeneca’s commitment to non-profitable access during the pandemic and the fact that AstraZeneca estimates that up to 3 billion doses will be available globally by 2021.